Biopharmaceutical Company Spiral Therapeutics, Inc. has obtained the authorization from the US Food and Drug Administration (FDA) to start in early 2018 of a phase 1 clinical trial with LPT99, a new molecule for the treatment of chemotherapy-induced hearing loss in pediatric patients.
LPT99 is a small molecule with strong anti-apoptotic activity. LPT99 is administered transtympanically in a hydrogel formulation to effectively reach the hair cells in the inner ear. This molecule has confirmed to be safe and effective in the animal model tests carried out by the Neurobiology of Hearing group, within the framework of an agreement with that company that began in 2015 and continues today.